DIESSE ANNOUNCES THE FIRST SARS-CoV-2 NEUTRALIZING ANTIBODIES RESEARCH KIT, USEFUL FOR MEASURING THE EFFECTIVENESS OF VACCINES
Siena, 10th December 2020 - Thanks to DIESSE Diagnostica Senese, starting from January 2021 a new test will be available to laboratory medicine. The test, which provides information on the immune status of patients who have contracted COVID-19, will also be useful in measuring the effectiveness of future vaccines.
The new test, called Chorus SARS-CoV-2 Neutralizing Ab, uses quantitative determination of total neutralizing antibodies in serum to establish whether the patient has developed an immune response capable of protecting them from further infection from the SARS-CoV-2 virus.
The test promises higher specificity levels when compared with more direct methods and is the fruition of a collaborative project between DIESSE and the MAD (Monoclonal Antibody Discovery) LAB group at Toscana Life Sciences foundation, coordinated by Dr. Rappuoli, that developed the specific therapeutic antibody used in the test. DIESSE develop a test which offers the quantitative determination of total neutralizing SARS-CoV-2 antibodies IgG, IgM, and IgA.
This innovative and important achievement adds to the range of serological tests for detecting the IgG, IgA and IgM antibodies, as well as the total immunoglobulins specific to SARS-CoV-2, along with the nasopharyngeal antigen test, all of which are currently available on DIESSE’s Chorus Trio automated system.
“Another important milestone for the research and development team here at DIESSE,” says the company’s Commercial Operations Director, Luigi Nava, “made possible due to the perseverance and competence of our colleagues, in partnership with one of the most important players of the Italian scientific scene”.